| Size | Price | |
|---|---|---|
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
5-Aminoimidazol-4-carboxamide is an aminoimidazolium compound with an amino group at C-5 and a formamid group at C-4. It is a mouse metabolite. It is an aminoimidazolium and monocarboxylic acid amide. 5-Aminoimidazol-4-carboxamide is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain). It has also been reported in Pogostemon cablin, Euglena gracilis, and Phaseolus vulgaris, with relevant data available. It is an imidazole derivative and a metabolite of the antitumor drugs BIC and DIC. It can be used, either directly or as a ribonucleotide, as a condensing agent in the preparation of nucleosides and nucleotides. It is used in combination with orotic acid to treat liver diseases.
Drug Indications It has been studied for the treatment of allergic rhinitis and pediatric diseases. |
| Exact Mass |
126.054
|
|---|---|
| CAS # |
360-97-4
|
| Related CAS # |
5-Amino-3H-imidazole-4-carboxamide hydrochloride;72-40-2
|
| PubChem CID |
9679
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
535.4±60.0 °C at 760 mmHg
|
| Melting Point |
164-170 °C(lit.)
|
| Flash Point |
277.6±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.799
|
| LogP |
-1.01
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
126
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C(N)NC=N1)N
|
| InChi Key |
DVNYTAVYBRSTGK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H6N4O/c5-3-2(4(6)9)7-1-8-3/h1H,5H2,(H2,6,9)(H,7,8)
|
| Chemical Name |
4-amino-1H-imidazole-5-carboxamide
|
| Synonyms |
Aminoimidazole Carboxamide Diazol-C Colahepat
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~792.90 mM)
H2O : ~20 mg/mL (~158.58 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 15 mg/mL (118.93 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00004314 | COMPLETED | Drug: aminomidazole carboxamide riboside | Lesch-Nyhan Syndrome | National Center for Research Resources (NCRR) | 1996-02 | Phase 2 |
| NCT01193959 | COMPLETED | Non-small Cell Lung Cancer (NSCLC) | Armando Santoro, MD | 2010-09 | ||
| NCT06279767 | RECRUITING | Drug: 6-mercaptopurine | Cancer Glioblastoma Temozolomide |
The First Affiliated Hospital with Nanjing Medical University | 2022-07-01 | Phase 1 Phase 2 |
| NCT01055522 | TERMINATED | Drug: Arm 1: L19IL2 + Dacarbazine Drug: Arm 3: Dacarbazine Drug: ARM 2: L19IL2 + Dacarbazine |
Metastatic Melanoma | Philogen S.p.A | 2008-06 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
